Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Study of E7090 Alone and With Endocrine Therapy in ER+ HER2- Recurrent/Metastatic Breast Cancer
jRCT2080225333Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tasurgratinib in breast cancer (3 arms), sponsored by Eisai Co., Ltd. Started Aug 2020; status: completed.
02
Drugs
tasurgratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080225333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225333.